Mabqi
- Company typePrivate
- Founded2017
- HeadquartersMontpellier, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
Mabqi firmographics
Firmographics- Name
- Mabqi
- Legal name
- MABQI S.A.S.
- Website
- https://mabqi.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Mabqi industry classification
Industry- Product category
- Biopharmaceutical R&D Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
Keywords
Where Mabqi is headquartered
LocationHeadquarters
- HQ city
- Montpellier
- HQ country
- France
- HQ region
- Europe
Offices3 records
Markets served
Mabqi business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Partnership and Collaborative Research Agreements: Mabqi generates revenue through fee-for-service discovery partnerships with biopharma companies, where it applies its LiteMab platform to discover antibodies against targets defined by partners. Revenue is earned at project milestones (hit identification, lead selection, IND-enabling studies).
- Licensing and Milestone Payments: The company earns licensing revenue and milestone payments when partnered antibody programs advance through development and regulatory stages. The Syndivia ADC licensing agreement (January 2026) exemplifies this model, where an option on a jointly discovered ADC was exercised by a pharma company, generating licensing income.
- Non-Dilutive Public Funding: Mabqi supplements its operations through non-dilutive public funding grants, notably the €5 million France 2030 award in 2025 to advance lead candidate MQI-201. This supports preclinical development and IND-enabling studies without equity dilution.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Mabqi product offering
Product offeringCore offering
Mabqi is a biopharmaceutical company that discovers and develops next-generation therapeutic antibodies and immunotherapies, primarily in oncology. The company operates the LiteMab© Antibody Discovery Studio, an integrated platform combining proprietary fully human synthetic antibody libraries (HuscI2 and pHuscI2) with AI-powered phage and yeast display technologies to deliver developable therapeutic antibody candidates in approximately 4 months. Mabqi offers fee-for-service discovery partnerships, co-development collaborations, and licensing arrangements to biopharma clients, and is also advancing a proprietary pipeline including MQI-201 and MQI-181.
Product overview
Mabqi offers a unified antibody discovery ecosystem centered on the LiteMab© Antibody Discovery Studio, which integrates three core platforms: LiteMab© for conventional fully human antibody discovery from proprietary synthetic libraries; LiteMab© Sense for conditionally active pH-sensitive tumor-selective antibodies; and LiteMab© Neo for affinity maturation and LiteMab© Neo Sense for pH-sensitive maturation. The company leverages AI-powered phage and yeast display technologies to deliver readily developable therapeutic candidates across formats including conventional mAbs, bispecifics/multispecifics, T-cell engagers (TCEs), and antibody-drug conjugates (ADCs). Mabqi's proprietary pipeline includes MQI-201 (first-in-class anti-TRPV6 antibody for solid tumors, entering clinical development) and MQI-181 (pH-sensitive ADC for hemato-oncology), alongside multiple discovery-stage programs. Services include antibody characterization, developability assessment, and functional validation through internalization and cytotoxicity assays.
Differentiator
Problem solved
Functional benefit
Products and services
- LiteMab© Antibody Discovery Studio Comprehensive integrated antibody discovery platform combining proprietary fully human synthetic libraries with AI-powered phage and yeast display technologies for high-throughput selection, screening, and functional validation of therapeutic antibody candidates. Supports conventional mAbs, bispecifics, multispecifics, T-cell engagers, pH-sensitive antibodies, and ADCs.
- LiteMab© (Core Antibody Discovery) Core antibody discovery offering powered by proprietary high-diversity fully human synthetic antibody libraries spanning broad structural and paratope landscapes. Enables discovery of conventional antibodies including against complex and difficult targets such as GPCRs and ion channels.
- LiteMab© Sense (pH-Sensitive Antibodies) Conditionally active pH-sensitive antibody discovery offering leveraging a proprietary fully human synthetic pH-sensitive naive library (pHuscI2). Generates tumor-selective antibodies that preferentially bind in the acidic tumor microenvironment while showing reduced binding at physiological pH, enhancing specificity and reducing off-tumor toxicity.
- LiteMab© Neo (Affinity Maturation) Affinity maturation platform for next-generation biologics. Provides customized library design based on parental sequences with AI-powered dual display technology enabling precise tuning of affinity, pH sensitivity, and functional activity while preserving developability.
- Antibody Drug Conjugate (ADC) Discovery ADC discovery service combining targeting specificity of monoclonal antibodies with potent cytotoxicity of chemotherapeutic agents. Supports generation of native or pH-sensitive antibodies using AI-powered dual display for rapid clone identification, hit characterization, and functional validation including internalization assays and cytotoxicity testing.
- Bispecific & Multispecific Antibody Discovery Discovery service delivering high-affinity binders tailored for complex bispecific, multispecific, and T-cell engager (TCE) formats. Leverages AI-powered dual-display workflows and synthetic libraries with scFv format enabling rapid assembly and flexible combination of binding domains.
- MQI-201 (Anti-TRPV6 Antibody Candidate) First-in-class anti-TRPV6 antibody therapeutic candidate for solid tumors. Demonstrated safety and efficacy in metastatic prostate cancer, sarcoma, and pancreas cancer preclinical models. Target for Phase I clinical study early 2027. Developed for partnering and licensing to biopharma.
- MQI-181 (pH-Sensitive ADC) pH-sensitive Antibody Drug Conjugate for hemato-oncology. Novel tumor-specific immunotherapy designed for lymphoma and blood cancers, targeting the tumor microenvironment with potential to evolve into next-generation ADC format. Currently in preclinical stage with in-vivo data available, open for partnering.
Quantifiable outcome
- 4-month timeline from target to validated lead
- +3 more outcomes
Companies that use Mabqi
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles1 record
Mabqi technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Mabqi partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, minor and major.
- SyndiviacoreMabqi and Syndivia entered a research collaboration in 2023 to discover and develop a new ADC drug candidate with indications in prostate cancer. Mabqi's LiteMab Antibody Discovery Studio identified the antibody, which was then tailored to meet precise functional requirements including affinity, developability, and pharmacological properties. Syndivia designed the final ADC candidate and conducted full preclinical characterization using its GeminiMab ADC platform. Syndivia exercised an option on the jointly discovered DAR1 ADC, which was subsequently acquired by a leading pharmaceutical company in January 2026.
- IOME BiominorMabqi co-authored a scientific publication with IOME Bio on the discovery and preclinical characterization of potent anti-RGMb antibodies blocking multiple ligand bindings, published in mAbs (2024). IOME Bio led the research project focused on the Repulsive Guidance Molecule b (RGMb) co-inhibitory pathway in T cells for anti-tumor immunity enhancement.
- AbzenacoreMabqi and Abzena established a strategic partnership integrating Mabqi's LiteMab Antibody Discovery Studio with Abzena's development and manufacturing capabilities to offer biopharma customers a streamlined end-to-end drug development solution. The collaboration leverages Mabqi's hit screening, characterization, and lead selection using universal and pH-sensitive libraries, combined with Abzena's capabilities for developability, cell line development, process development, and GMP manufacturing. Both organizations support a broad range of modalities including monoclonal antibodies, mAb fragments, bispecifics, multispecifics, and bioconjugates.
- Paris Saclay Cancer Cluster (PSCC)coreMabqi joined PSCC Connect, the Paris-Saclay Cancer Cluster network. PSCC is a world-class innovation hub dedicated to accelerating cancer research, therapy development, and patient care by bringing together academic institutions, hospitals, and biotech companies. Mabqi was subsequently selected for the PSCC BOOST Programme, providing tailored scientific and medical support, access to expert ecosystem, hospital networks, industry partners, and investors to accelerate development of its lead asset toward clinical stages.
- SATT NordmajorSATT Nord (Société d'Accélération du Transfert de Technologies) collaborated with Mabqi and INSERM teams in Lille on the discovery and characterization of the first-in-class MQI-201 anti-TRPV6 antibody. SATT Nord manages technology transfer for research institutions in Northern France.
- INSERM (Lille)majorINSERM research teams in Lille collaborated with Mabqi on the discovery of the MQI-201 anti-TRPV6 antibody. The academic partnership contributed scientific expertise in ion channel biology and oncology research, resulting in a first-in-class therapeutic antibody candidate with demonstrated efficacy in prostate cancer models.
- Business France (France 2030 Export Program)minorMabqi was selected for the France 2030 Export program, a strategic initiative supporting France's most innovative companies in international expansion. The program provides high-impact export support including global visibility, targeted international missions, and strategic expertise. Business France, the French government agency for international development, manages the program.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
Mabqi competitors and assessment
Company assessmentDirect peers
- Adimab: Adimab operates a yeast display-based antibody discovery platform serving biopharma partners with fully human antibody leads—directly comparable to Mabqi's LiteMab platform in technology, B2B service model, and target customer base.
- AbCellera: AbCellera is an AI-powered antibody discovery company combining immune repertoire sequencing with high-throughput screening—comparable to Mabqi's AI-powered dual display platform in tech approach and biopharma service offering.
- Yumab: Yumab is a German antibody discovery CRO offering fully human antibody generation via in silico and phage display technologies—a similarly sized European peer with overlapping service offerings and customer base.
- Trianni: Trianni provides transgenic human antibody platform technology (Trianni Mouse) for fully human antibody discovery—comparable to Mabqi's synthetic library approach in delivering IP-clean, fully human antibodies to biopharma partners.
- AbTherx: AbTherx is an antibody platform company with proprietary transgenic and AI-enabled discovery technologies—competes with Mabqi in the antibody discovery services market with a similar technology-driven value proposition.
- Specifica: Specifica is an antibody discovery company specializing in next-generation phage display libraries—a directly comparable platform peer offering antibody library-based discovery services to biopharma partners.
- Numab Therapeutics: Numab is a Swiss biotech developing multispecific antibody therapeutics using a proprietary antibody fragment platform—comparable to Mabqi in European origin, antibody platform technology, and therapeutic pipeline focus in oncology.
- Harbour BioMed: Harbour BioMed operates a transgenic animal-based antibody discovery platform (Harbour Mice) for fully human antibody generation—a comparable platform peer in antibody technology and biopharma partnership model.
Broad incumbents
- MorphoSys (Novartis): MorphoSys (acquired by Novartis in 2024) is a larger established antibody therapeutics company with proprietary antibody libraries and multiple approved/clinical assets—a broader incumbent operating in Mabqi's therapeutic space.
- WuXi Biologics: WuXi Biologics is a global contract development and manufacturing organization offering end-to-end biologics services including antibody discovery, development, and manufacturing—a broad incumbent serving Mabqi's customer base with integrated offerings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Mabqi social profiles
Digital presenceMabqi financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mabqi leadership team
Management profileNumber of profiles
Profiles12 records
Mabqi funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mabqi M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mabqi
What does Mabqi do?
Mabqi is a biopharmaceutical company that discovers and develops next-generation therapeutic antibodies and immunotherapies, primarily in oncology. The company operates the LiteMab© Antibody Discovery Studio, an integrated platform combining proprietary fully human synthetic antibody libraries (HuscI2 and pHuscI2) with AI-powered phage and yeast display technologies to deliver developable therapeutic antibody candidates in approximately 4 months. Mabqi offers fee-for-service discovery partnerships, co-development collaborations, and licensing arrangements to biopharma clients, and is also advancing a proprietary pipeline including MQI-201 and MQI-181.
Is Mabqi a public or private company?
Mabqi is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Mabqi founded?
Mabqi was founded in 2017. It employs 11 to 50 people.
Where is Mabqi based?
Mabqi is headquartered in Montpellier, France, in the Europe region.
How does Mabqi make money?
Three revenue lines are on record. Partnership and Collaborative Research Agreements are the primary driver. The others are licensing and Milestone Payments and non-Dilutive Public Funding.
Who are Mabqi's main competitors?
Direct peers on record are Adimab, AbCellera, Yumab, Trianni, AbTherx, Specifica, Numab Therapeutics and Harbour BioMed. Broad incumbents are MorphoSys (Novartis) and WuXi Biologics.
Does Mabqi have an API?
No public API is recorded for Mabqi.
What industry is Mabqi in?
Mabqi's product category is Biopharmaceutical R&D Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.